심리적도박 | Cases and Studies in Pathological Gambling | 游戏设计
- date : 2015-05-20 01:10|hit : 2770
-
- Review] Pathologic Gambling: Biological and Clinical Considerations
-
DocNo of ILP: 3091
Doc. Type: Review
Title: Pathologic Gambling: Biological and Clinical Considerations
Authors: Topf, JL; Yip, SW; Potenza, MN
Full Name of Authors: Topf, Jocelyn L.; Yip, Sarah W.; Potenza, Marc N.
Keywords by Author: pathologic gambling; impulse control disorders; substance use disorders
Keywords Plus: IMPULSE-CONTROL DISORDERS; NATIONAL EPIDEMIOLOGIC SURVEY; PLACEBO-CONTROLLED TRIAL; N-ACETYL CYSTEINE; DOUBLE-BLIND; IMAGINAL DESENSITIZATION; RELAPSE PREVENTION; ALCOHOL DEPENDENCE; PROBLEM GAMBLERS; DRUG-ADDICTION
Abstract: Pathologic gambling (PG) is categorized as an impulse control disorder. Phenomenologic, neurobiologic, and pharmacologic data suggest similarities in the pathophysiologies of substance use disorders and PG. Both behavioral and pharmacologic approaches, including those that have been empirically validated for substance use disorders, have shown promise in the treatment of PG. Findings from biologic studies of PG are reviewed, and treatment approaches based on controlled Studies are summarized.
Cate of OECD: Health sciences
Year of Publication: 2009
Business Area: gamble
Detail Business: gamble
Country: USA
Study Area:
Name of Journal: JOURNAL OF ADDICTION MEDICINE
Language: English
Country of Authors: Yale Univ, Sch Med, Connecticut Mental Hlth Ctr, Dept Psychiat, New Haven, CT 06508 USA; Yale Univ, Sch Med, Connecticut Mental Hlth Ctr, Ctr Child Study, New Haven, CT 06508 USA
Press Adress: Potenza, MN (reprint author), SAC, CMHC, Room S-104,34 Pk St, New Haven, CT 06519 USA.
Email Address: marc.potenza@yale.edu
Citaion:
Funding: VA VISNI MIRECC; REAP; Women's Health Research [P50-DA16556, P50-DA9241, P50-AA15632, RL1-AA017539, R01 DA019039]; National Institutes of Health
Lists of Citation: American Psychiatric Association Committee of Nomenclature and Statistics, 1980, DIAGN STAT MAN MENT; American Psychiatric Association Committee on Nomenclature and Statistics, 1994, DIAGN STAT MAN MENT; Bechara Antoine, 2003, J Gambl Stud, V19, P23, DOI 10.1023/A:1021223113233; Bergh C, 1997, PSYCHOL MED, V27, P473, DOI 10.1017/S0033291796003789; Bjork JM, 2004, J NEUROSCI, V24, P1793, DOI 10.1523/JNEUROSCI.4862-03.2004; Black DW, 2007, J CLIN PSYCHOPHARM, V27, P143, DOI 10.1097/jcp.0b013e3180337fe2; Black DW, 2004, J CLIN PSYCHOPHARM, V24, P108, DOI 10.1097/01.jcp.0000114844.58996.4a; Blumberg HP, 2003, ARCH GEN PSYCHIAT, V60, P601, DOI 10.1001/archpsyc.60.6.601; Breiter HC, 1996, NEUROIMAGE, V4, pS127, DOI 10.1006/nimg.1996.0063; Brewer JA, 2008, BIOCHEM PHARMACOL, V75, P63, DOI 10.1016/j.bcp.2007.06.043; Cardinal RN, 2006, NEURAL NETWORKS, V19, P1277, DOI 10.1016/j.neunet.2006.03.004; Comings D.E., 1998, CNS SPECTRUMS, V3, P20; Coric V, 2007, J CLIN PSYCHIAT, V68, P170; da Silva Lobo DS, 2007, J GAMBL STUD, V23, P421, DOI DOI 10.1007/S10899-007-9060-X; De Castro IP, 1999, PHARMACOGENETICS, V9, P397; Decaria CM, 1998, CNS SPECTRUMS, V3, P38; Desai RA, 2007, PSYCHOL ADDICT BEHAV, V21, P431, DOI 10.1037/0893-164X.21.4.431; DESAI RA, 2009, J CLIN PSYCHIAT, pE1; Dick DM, 2007, ALCOHOL CLIN EXP RES, V31, P1645, DOI 10.1111/j.1530-0277.2007.00470.x; Dutra L, 2008, AM J PSYCHIAT, V165, P179, DOI 10.1176/appi.ajp.2007.06111851; Echeburua E, 1996, BEHAV COGN PSYCHOTH, V24, P51; Echeburua E, 2000, BEHAV THER, V31, P351, DOI 10.1016/S0005-7894(00)80019-2; FilsAime ML, 1996, ARCH GEN PSYCHIAT, V53, P211; Fong T, 2008, PHARMACOL BIOCHEM BE, V89, P298, DOI 10.1016/j.pbb.2007.12.025; Grant JE, 2008, J CLIN PSYCHIAT, V69, P783; Grant JE, 2006, AM J PSYCHIAT, V163, P303, DOI 10.1176/appi.ajp.163.2.303; Grant JE, 2006, INT CLIN PSYCHOPHARM, V21, P203, DOI 10.1097/00004850-200607000-00002; Grant JE, 2008, PSYCHOPHARMACOLOGY, V200, P521, DOI 10.1007/s00213-008-1235-3; Grant JE, 2005, AM J PSYCHIAT, V162, P2184, DOI 10.1176/appi.ajp.162.11.2184; Grant JE, 2007, BIOL PSYCHIAT, V62, P652, DOI 10.1016/j.biopsych.2006.11.021; Grant JE, 2003, INT CLIN PSYCHOPHARM, V18, P243, DOI 10.1097/01.yic.0000073881.93678.21; Hodgins DC, 2001, J CONSULT CLIN PSYCH, V69, P50, DOI 10.1037//0022-006X.69.1.50; HOFFMANN J, 1999, REPORT NATL GAMBLING; Hollander E, 2005, WORLD J BIOL PSYCHIA, V6, P113, DOI 10.1080/15622970510029768; Hollander E, 2000, BIOL PSYCHIAT, V47, P813, DOI 10.1016/S0006-3223(00)00241-9; Hollander E, 2005, AM J PSYCHIAT, V162, P137, DOI 10.1176/appi.ajp.162.1.137; Hommer DW, 2004, ALCOHOL CLIN EXP RES, V28, p22A; Ib??ez Angela, 2003, J Gambl Stud, V19, P11, DOI 10.1023/A:1021271029163; JAMES KC, 1999, NATL GAMBLING IMPACT; Johnson BA, 2004, CNS DRUGS, V18, P1105, DOI 10.2165/00023210-200418150-00005; Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403; Kim SW, 1998, J CLIN PSYCHIAT, V59, P159; Kim SW, 2002, J CLIN PSYCHIAT, V63, P501; Kim SW, 2001, BIOL PSYCHIAT, V49, P914, DOI 10.1016/S0006-3223(01)01079-4; Knutson B, 2003, NEUROIMAGE, V18, P263, DOI 10.1016/S1053-8119(02)00057-5; Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583; Ladd GT, 2002, PSYCHOL ADDICT BEHAV, V16, P76, DOI 10.1037//0893-164X.16.1.76; Ladouceur R, 2001, J NERV MENT DIS, V189, P774, DOI 10.1097/00005053-200111000-00007; Ladouceur R, 2003, BEHAV RES THER, V41, P587, DOI 10.1016/S0005-7967(02)00036-0; McClure SM, 2004, SCIENCE, V306, P503, DOI 10.1126/science.1100907; MCCONAGHY N, 1991, BRIT J PSYCHIAT, V159, P390, DOI 10.1192/bjp.159.3.390; MCCONAGHY N, 1983, BRIT J PSYCHIAT, V142, P366, DOI 10.1192/bjp.142.4.366; McElroy SL, 2008, J CLIN PSYCHIAT, V69, P433; Meyer G, 2004, PSYCHONEUROENDOCRINO, V29, P1272, DOI 10.1016/j.psyneuen.2004.03.005; Morasco BJ, 2006, GEN HOSP PSYCHIAT, V28, P94, DOI 10.1016/j.genhosppsych.2005.09.004; Moreno IS-RJ, 1991, HUMAN PSYCHOPHARMA S, V6, P9; National Research Council, 1999, PATH GAMBL CRIT REV; Nordin C, 2006, J PSYCHIAT RES, V40, P454, DOI 10.1016/j.jpsychires.2005.06.003; Nordin C, 1999, CNS Spectr, V4, P25; O'Brien CP, 2005, AM J PSYCHIAT, V162, P1423, DOI 10.1176/appi.ajp.162.8.1423; Odlaug BL, 2007, J CLIN PSYCHOPHARM, V27, P227, DOI 10.1097/01.jcp.0000264976.86990.00; Oslin DW, 2003, NEUROPSYCHOPHARMACOL, V28, P1546, DOI 10.1038/sj.npp.1300219; Pallanti S, 2002, J CLIN PSYCHIAT, V63, P559; Pallanti S, 2006, CNS SPECTRUMS, V11, P956; Pasternak AV, 1999, ARCH FAM MED, V8, P515, DOI 10.1001/archfami.8.6.515; PEARLSON GD, 2007, ABNORMAL FMRI ACTIVA; Petry NM, 2003, ADDICT BEHAV, V28, P1049, DOI 10.1016/S0306-4603(02)00233-2; Petry NM, 2006, J CONSULT CLIN PSYCH, V74, P555, DOI 10.1037/0022-006X.74.3.555; Petry NM, 2005, J GAMBL STUD, V21, P27, DOI 10.1007/s10899-004-1919-5; Petry NM, 2005, J CLIN PSYCHIAT, V66, P564; Pittenger C, 2005, J CLIN PSYCHIAT, V66, P1492; Potenza MN, 2003, ARCH GEN PSYCHIAT, V60, P828, DOI 10.1001/archpsyc.60.8.828; Potenza MN, 2008, PHILOS T R SOC B, V363, P3181, DOI 10.1098/rstb.2008.0100; Potenza M.N., 2002, NEUROPSYCHOPHARMACOL, P1725; Potenza MN, 2003, AM J PSYCHIAT, V160, P1990, DOI 10.1176/appi.ajp.160.11.1990; Potenza MN, 2007, NAT CLIN PRACT NEURO, V3, P664, DOI 10.1038/ncpneuro0680; Potenza MN, 2002, J GEN INTERN MED, V17, P721, DOI 10.1046/j.1525-1497.2002.10812.x; Ratsma JE, 2002, ALCOHOL ALCOHOLISM, V37, P522, DOI 10.1093/alcalc/37.6.522; Reuter J, 2005, NAT NEUROSCI, V8, P147, DOI 10.1038/nn1378; ROY A, 1988, ARCH GEN PSYCHIAT, V45, P369; ROY A, 1989, ARCH GEN PSYCHIAT, V46, P679; Saiz-Ruiz J, 2005, J CLIN PSYCHIAT, V66, P28; Shinohara Kikunori, 1999, Applied Human Science, V18, P37, DOI 10.2114/jpa.18.37; Slutske WS, 2000, ARCH GEN PSYCHIAT, V57, P666, DOI 10.1001/archpsyc.57.7.666; STEWART RM, 1988, BRIT J PSYCHIAT, V152, P284, DOI 10.1192/bjp.152.2.284; Sylvain C, 1997, J CONSULT CLIN PSYCH, V65, P727, DOI 10.1037//0022-006X.65.5.727; Tanabe J, 2007, HUM BRAIN MAPP, V28, P1276, DOI 10.1002/hbm.20344; Weinshenker D, 2007, NEUROPSYCHOPHARMACOL, V32, P1433, DOI 10.1038/sj.npp.1301263; WEINTRAUB D, 2008, DOPAMINERGIC THERAPY; Weintraub D, 2006, ARCH NEUROL-CHICAGO, V63, P969, DOI 10.1001/archneur.63.7.969; Wrase J, 2007, NEUROIMAGE, V35, P787, DOI 10.1016/j.neuroimage.2006.11.043; Zack M, 2007, NEUROPSYCHOPHARMACOL, V32, P1678, DOI 10.1038/sj.npp.1301295; Zack M, 2004, NEUROPSYCHOPHARMACOL, V29, P195, DOI 10.1038/sj.npp.1300333
Number of Citaion: 93
Publication: LIPPINCOTT WILLIAMS & WILKINS
City of Publication: PHILADELPHIA
Address of Publication: 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
ISSN: 1932-0620
29-Character Source Abbreviation: J ADDICT MED
ISO Source Abbreviation: J. Addict. Med.
Volume: 3
Version: 3
Start of File: 111
End of File: 119
DOI:
Number of Pages: 9
Web of Science Category: Substance Abuse
Subject Category: Substance Abuse
Document Delivery Number: 491LQ
Unique Article Identifier: WOS:000269580700001
[이 게시물은 HyeJung Mo…님에 의해 2015-05-20 20:14:55 GAMBLING에서 이동 됨]
- reply : 0
-
- list
-
- prev
- next